for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

GNI Group Ltd

2160.T

Latest Trade

1,707.00JPY

Change

33.00(+1.97%)

Volume

536,300

Today's Range

1,648.00

 - 

1,728.00

52 Week Range

835.33

 - 

2,148.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
1,674.00
Open
1,653.00
Volume
536,300
3M AVG Volume
14.56
Today's High
1,728.00
Today's Low
1,648.00
52 Week High
2,148.00
52 Week Low
835.33
Shares Out (MIL)
43.34
Market Cap (MIL)
72,551.24
Forward P/E
--
Dividend (Yield %)
--

Next Event

Dividend For 2160.T - 0.0000 JPY

Latest Developments

More

GNI Group unit receives marketing approval for Bi-Ostetic Bioactive Glass Foam related product

GNI Group gets IND clearance by FDA for liver fibrosis treatment

GNI Group unit says clearance of IND by FDA for F351 clinical trials in the treatment of liver fibrosis

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About GNI Group Ltd

GNI Group Ltd. is a Japan-based company engaged in new drug production activities utilizing biotechnologies. The Company is engaged in the development of therapeutic agents for diseases that have many sufferers in Asian countries such as Japan and China, as well as clinical trial and bio-verification test businesses. It is engaged in research and development of therapeutic agents, including F647 for radiation pneumonia (RP) and idiopathic pulmonary fibrosis (IPF), F351 for liver fibrosis (cirrhosis) and F573 for acute hepatic insufficiency and acute chronic liver failure (ACLF).

Industry

Biotechnology & Drugs

Contact Info

3F, Nihonbashi-Honcho YS Bldg

2-2-2, Nihonbashi Hon-cho

+81.3.62143600

http://www.gnipharma.com/

Executive Leadership

Ying Luo

President, Representative Executive Officer, Chief Executive Officer, Chairman and CEO of Subsidiaries, Director

Thomas Eastling

Chief Financial Officer, Representative Executive Officer, Director

Takashi Kataoka

Director

Sadayuki Yasukawa

Director

Wanshou Guo

Independent Director

Key Stats

Price To Earnings (TTM)
455.01
Price To Sales (TTM)
11.55
Price To Book (MRQ)
6.93
Price To Cash Flow (TTM)
81.73
Total Debt To Equity (MRQ)
23.46
LT Debt To Equity (MRQ)
15.03
Return on Investment (TTM)
5.26
Return on Equity (TTM)
4.01

Latest News

Latest News

BRIEF-GNI Group unit receives marketing approval for Bi-Ostetic Bioactive Glass Foam related product

* Says unit Berkeley Advanced Biomaterials receives marketing approval for Bi-Ostetic Bioactive Glass Foam related product in U.S. from FDA

BRIEF-GNI Group gets IND clearance by FDA for liver fibrosis treatment

* GNI Group announces clearance of investigational new drug (IND) by FDA for F351 clinical trials in the treatment of liver fibrosis

BRIEF- GNI Group unit says clearance of IND by FDA for F351 clinical trials in the treatment of liver fibrosis

* Says its wholly-owned subsidiary GNI USA, Inc had received U.S. FDA clearance on Sept. 29 (U.S. local time) for the Investigational New Drug application (IND) for F351 for U.S. clinical trials in the treatment of liver fibrosis

BRIEF-GNI Group says exercise of options

* Says 4,082 units of its 40th series options were exercised to 4.1 million shares of its common stock, from July 3 to July 18

BRIEF- GNI Group unit GNI USA to sell stake in IriSys for $3.8 mln and GNI Group to acquire stake in GNI-EPS (HONG KONG) HOLDINGS for $4.2 mln

* Says its wholly owned unit GNI USA, Inc will sell 242,029 voting rights in IriSys, LLC to EPS Americas, Corp., for $3.8 million (425.2 million yen), on July 31, and will cut voting power in IriSys, LLC to 15 percent from 35 percent

BRIEF-GNI Group says exercise of options

* Says 2,102 units of its 40th series options were exercised to 2,102,000 shares of its common stock from June 15 to June 20

BRIEF-GNI Group says exercise of options

* Says 5,909 units of its 40th series options were exercised to 5.9 million shares of its common stock, from June 13 to June 14

BRIEF- GNI Group announces exercise of options

* Says 2,196 units of its 40th series options were exercised to 2.2 million shares of its common stock from June 5 to June 12

BRIEF- GNI Group announces exercise of options

* Says 2,055 units of its 40th series options were exercised to 2.1 million shares of its common stock on June 1 and June 2

BRIEF-GNI Group announces exercise of options

* Says 2,536 of its 40th series options were exercised to 2.5 million shares, during period from May 9 to May 25

CORRECTED-OFFICIAL-BRIEF-GNI Group to acquire Berkeley Advanced Biomaterials through GNI USA(April 18)

* Says it will acquire 70 percent voting power of a new unit of Berkeley Advanced Biomaterials, Inc., for $59.7 million (6.51 billion yen), through GNI USA, Inc.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up